The Haemophilus Influenzae Infection Treatment Market is expected to grow on an irreversible note in the next 10 years. The future scenario would be data-driven healthcare. This would, in turn, widen the potential for enhancing treatment options. With interoperability taking the centre stage, program participants could access app blueprints, data templates, and security tools. Thus, the big data cloud would turn out to be kinetic. This would result in an upswing in the healthcare vertical going forward.
It is important to monitor the resistance rates (in the hospital or the region) of H influenzae to the different antibiotics to guide empiric antimicrobial choices while awaiting susceptibility results. Oral agents active against nontypeable strains include amoxicillin-clavulanate, fluoroquinolones, macrolides (e.g., azithromycin, clarithromycin), and various extended spectrum cephalosporins (e.g., cefixime, cefpodoxime, loracarbef, cefuroxime).
Get Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/23044
The global market for Haemophilus Influenzae Infection Treatment market can be segmented on basis of treatment and geography:
| Treatment |
|
Nontypeable H. influenzae is the most common cause of exacerbations of COPD in adults. Approximately, 24 million Americans have COPD and experience intermittent exacerbations, many caused by bacterial infection. Thus, H. influenzae infections are highly prevalent among adults with COPD.
There are two major drugs class which are effective in haemophilus influenzae infection treatment namely, antibiotics and glucocorticoids. In antibiotics, penicillin are useful in management of mucosal infections caused by nonencapsulated H influenzae. However, up to 25%-50% of isolates produce beta-lactamase so are resistant to this class of drugs.
Third-generation cephalosporins are highly effective in H influenzae infections. Meropenem or ampicillin and chloramphenicol are alternative regimens.
Some of the common drugs available in the market under this drug class category are Azithromycin (Zithromax), Ceftriaxone (Rocephin), Cefuroxime (Ceftin, Zinacef), Ampicillin (Marcillin, Omnipen, Polycillin, Principen), Amoxicillin (Trimox, Amoxil, Trimox), Amoxicillin and clavulanic acid (Augmentin), Chloramphenicol (Chloromycetin), Erythromycin and sulfisoxazole (Eryzole, Pediazole), Meropenem (Merrem IV), and Rifampin (Rifadin).
For the entire list of market players, request for Table of Content here @ https://www.persistencemarketresearch.com/toc/23044
Glucocorticoids is the other drug class used for the treatment of H influenza. These agents are used as adjunctive therapy in H influenza meningitis for the anti-inflammatory effects and prevention of sensorineural deafness. The common drugs available in this class for the treatment of H influenza infection is Dexamethasone (Decadron, Baldex).
However, adverse effects of this drug class are hyperglycemia, hypertension, weight loss, GI bleeding or perforation synthesis, cerebral palsy, adrenal suppression, and death. Most of the adverse effects of corticosteroids are dose-dependent or duration-dependent.
On the basis of regional presence, global haemophilus influenzae infection treatment market can be segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
North America and Europe are together expected to dominate the global haemophilus influenzae infection treatment market due to upcoming approvals, more number of research and awareness.
Pre-Book Right Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/23044
There are some companies which are in to development and commercialization of products in this field, such as Takeda Pharmaceutical Company Limited, Merck & Co., Inc etc.
About us: Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com